---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-168569"
form_type: "8-K"
ticker: "SABS"
cik: "0001833214"
company_name: "SAB Biotherapeutics, Inc."
filed_at: "2026-04-22T23:59:59+00:00"
generated_at: "2026-05-15T04:55:36.673008+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# SAB BIO reports positive Phase 1 SAB-142 data: C-peptide preservation, T cell exhaustion, improved glycemic control

## Summary
- All 4 T1D participants on SAB-142 2.5 mg/kg preserved C-peptide; 3 of 4 achieved super responder status with C-peptide above baseline at Day 120.
- SAB-142 induced CD4+ Tconv cell exhaustion (TIGIT+ levels) correlating with C-peptide preservation, consistent with rabbit ATG mechanism.
- Mean CGM time in range improved from 73% at baseline to 85% at Day 120, with no increase in exogenous insulin use.
- Phase 2b SAFEGUARD trial topline data expected in 2H 2027; CEO cites potential best-in-class profile for T1D.

## SEC filing metadata
- accession: 0001193125-26-168569
- form_type: 8-K
- ticker: SABS
- cik: 0001833214
- company_name: SAB Biotherapeutics, Inc.
- filed_at: 2026-04-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1833214/000119312526168569/0001193125-26-168569-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1833214/000119312526168569/sabs-20260422.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-168569
- JSON: https://secwatch.observer/filing/0001193125-26-168569.json
- Plain text: https://secwatch.observer/filing/0001193125-26-168569.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.